A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
106actual
Sites
52
Countries
Belgium, Czechia, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-05 | actual | When the study began enrolling |
| Primary completion | 2025-10-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-29 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndromes
Intervention
- Drug: Luspatercept — also filed as BMS-986346, ACE-536, REBLOZYL
Primary outcome
what the primary-completion date above is the date OFNumber of participants who achieve red blood cell transfusion independence (RBC-TI) for 8 weeks with a simultaneous mean hemoglobin (Hb) increase of ≥ 1 g/dL from Week 1 to Week 24
measured Up to week 24
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed